WASHINGTON, Sept 26: US health regulators have strengthened the warnings on two blood cancer drugs to reflect the risk that they may reactivate the hepatitis B virus in patients previously infected with the disease. The warnings affect GlaxoSmithKline Plc’s Arzerra, which was approved in the United States in 2009 to treat chronic lymphocytic leukemia (CLL); and Rituxan, a drug made by Roche Holding AG and Biogen Idec Inc that is approved to treat a variety of conditions including CLL, non-Hodgkin’s Lymphoma and rheumatoid arthritis.
(agencies)
Follow our WhatsApp channel